Effects of Acute and Repeated Treatment with the Biased Mu Opioid Receptor Agonist TRV130 (Oliceridine) on Measures of Antinociception Gastrointestinal Function Abuse Liability in Rodents

摘要

RationaleTRV130 (oliceridine; N-[(3-methoxythiophen-2-yl)methyl]-2-[(9R)-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethanamine) is a novel mu opioid receptor (MOR) agonist that preferentially activates G-protein vs. β-arrestin signaling pathways coupled to MORs. Prevailing evidence suggests that TRV130 and other G-protein-biased MOR agonists may produce therapeutic analgesic effects with reduced adverse effects compared to existing MOR agonists.